Highlights the concerning trend of prescribing contraindicated direct oral anticoagulants (dabigatran and rivaroxaban) to hemodialysis patients with atrial fibrillation without supporting evidence.
More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support that the benefits outweigh the risks of these drugs in end-stage renal disease.
Chan et al. (Sat,) studied this question.